This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Emodin induces apoptosis in human prostate cancer cell LNCaP
Chun-Xiao Yu1, Xiao-Qian
Zhang2, Lu-Dong Kang1, Peng-Ju
Zhang1, Wei-Wen Chen1, Wen-Wen
Liu1, Qing-Wei Liu3,4, Jian-Ye Zhang1,4
1Department of Biochemistry and Molecular
Biology, Shandong University School of Medicine, Jinan 250012, China
2Merck Sharp & Dohme, Beijing 100738, China
3Positron Emission Tomography and Computer Tomography (PET-CT) Center, Shandong Provincial Hospital, Jinan
250021, China
Abstract
Aim: To elucidate effects and mechanisms of
emodin in prostate cancer cells.
Methods: Viability of emodin-treated LNCaP cells and PC-3 cells was measured by MTT assay. Following emodin treatments, DNA fragmentation was
assayed by agarose gel electrophoresis. Apoptosis rate and the expression of Fas and FasL were assayed
by flow cytometric analysis. The mRNA expression levels of androgen receptor (AR), prostate-specific antigen (PSA), p53,
p21, Bcl-2, Bax, caspase-3, -8, -9 and Fas were detected by RT-PCR, and the protein expression levels of AR, p53 and
p21 were detected by Western blot
analysis. Results: In contrast to PC-3, emodin caused a marked increase in
apoptosis and a decrease in cell proliferation in LNCaP cells. The expression of AR and PSA was decreased and the
expression of p53 and p21 was increased as the emodin concentrations were increased. In the same time, emodin
induced apoptosis of LNCaP cells through the upregulation of caspase-3 and -9, as well as the increase of Bax
/Bcl-2 ratio. However, it did not involve modulation of Fas or caspase-8 protein
expression. Conclusion: In prostate cancer
cell line, LNCaP, emodin inhibites the proliferation by AR and p53-p21 pathways, and induces apoptosis via the
mitochondrial pathway. (Asian J Androl 2008 Jul; 10: 625_634)
Keywords: emodin; prostate cancer; LNCaP; PC-3; proliferation; androgen receptor; p53; apoptosis; mitochondrial pathway
Correspondence to: Prof. Jian-Ye Zhang, Department of Biochemistry and Molecular Biology, Shandong University School of Medicine,
Jinan 250012, China.
Tel: +86-531-8838-2092
E-mail: zhjy@sdu.edu.cn
Dr Qing-Wei Liu, Positron Emission Tomography and Computer Tomography
(PET-CT) Center, Shandong Provincial Hospital, Jinan
250021, China.
Tel: +86-531-8706-0316
E-mail: liuqingwei6@yahoo.com.cn
Received 2007-05-23 Accepted 2008-01-11
DOI: 10.1111/j.1745-7262.2008.00397.x
1 Introduction
Prostate cancer is the most common malignant
disease and the second leading cause of death of male cancer
patients in the USA and in other developed countries [1].
Despite that early detection and diagnosis have been
improved recently, the incidence and mortality rates of this
cancer are still increasing steadily. Current prostate
cancer therapies such as surgery, chemotherapy and
radiation therapy are of limited efficacy and result in
significant side-effects. Androgen reduction therapy is
commonly used to control hormone-sensitive tumor cells;
however, ablation-resistant clones often emerge after
therapy [2]. Ablation-resistant prostate cancer is almost
incurable [3]. Therefore, novel effective therapies,
including biotherapy, are urgently needed to be developed.
In the search for alternative and preventive therapies
for prostate cancer, attention has been focused on plants.
Many phytochemicals such as genistein and curcumin
have been shown to possess substantial anticancer
activities in prostate cancer, and clinical trials using these
phytochemicals to prevent prostate cancer are ongoing
[4, 5]. Emodin (1,2,8-trihydroxy-6-methylanthraquinone),
an active component contained in the root and rhizome
of Rheum palmatum L. (Polygonaceae) [6, 7], has received
a great deal of attention recently. Several recent
observations have shown that emodin has anti-tumor, antibacterial,
diuretic and vasorelaxant effects [8_10]. Although it has
been claimed to have potent anticancer activity in the case
of prostate cancer [11], the molecular mechanisms of
emodin that produce its biological effects in prostate cancer
cells have not been well-characterized.
In the normal prostate, androgens play a critical role
in regulating the growth, differentiation and survival of
epithelial cells [12]. Evidence shows that androgens are
also involved in the development and progression of
prostate cancer. The biological effects of androgens in the
prostate are mediated by the androgen receptor (AR), a
ligand-activated transcription factor of the nuclear
receptor superfamily [13]. Therefore, the AR has a
critical role in the development of prostate cancer.
P53 protein is a transcription factor and regulates the
expression of several growth control genes involved in cell
cycle progression, DNA repair, apoptosis and angiogenesis
[14_16]. It is a major tumor suppressor that can lead to the
induction of a downstream target gene
p21waf1/cip1 to inhibit the cell cycles and cause cell growth arrest, and it is the key
in the cellular and molecular signaling cascades that guide
lethal DNA damage in cells to self-destruction.
Apoptosis is a major form of cell death and an
important process for normal development and suppression of
oncogenesis. It is characterized by a series of stereotypic
molecular features, such as activation of caspases and
expression and translocation of Bcl-2 family proteins.
Caspases, a family of cysteine proteases, play a critical
role during apoptosis. There are at least two major
mechanisms by which a caspase cascade results in the
activation of effector caspases (caspase-3, -6 and -7), one
involving caspase-8 and the other involving caspase-9 [17].
Therefore, two typical apoptosis pathways, receptor
(Fas)-mediated (involving caspase-8, death-inducing signal) and
chemical-induced (involving caspase-9, mitochondrial
pathway) apoptosis, have been suggested [18]. Moreover,
the Bcl-2 family proteins, such as Bcl-2 and Bax, are the
best-characterized regulators of apoptosis [19]. Many
reports have indicated that activation of caspase-3 is
blocked by anti-apoptosis members of the Bcl-2 family,
such as Bcl-2, and promoted by proapoptotic
members, such as Bax [20, 21].
The major purpose of the present study is to
investigate the effects of emodin on the proliferation and
apoptosis of prostate cancer cell line LNCaP and to
discover a possible mechanism involved in emodin actions
in prostate cancer cells.
2 Materials and methods
2.1 Cell cultures and treatments
The human prostate cancer cell lines LNCaP and
PC-3 were obtained from the American Type Culture Collection
(Manassas, VA, USA). LNCaP cell line was established
from a lymph node metastasis of a prostate cancer patient
and expressed mutant, but functional AR and a number of
androgen-inducible genes (e.g. prostate specific
antigen [PSA]). LNCaP and PC-3 cells were seeded in
35-mm culture dishes in RPMI 1640 medium (Gibco BRL,
Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum (FBS) and 5% CO2 at
37ºC until reaching approximately 50%_70% confluence. The cells were
maintained in serum-free RPMI 1640 medium for a
further 24 h and then treated with emodin at indicated
concentrations in RPMI 1640 medium containing 5% FBS.
Emodin (at 90% purity by HPLC; No. 45170; Sigma Chemical Company, St. Louis, MO, USA ) was dissolved
in dimethyl sulfoxide (DMSO), which also was used as a
control vehicle in the cell proliferation assay and in other
analyses/assays for the present study. In these assays,
every group received same amount of DMSO.
2.2 Cell proliferation assay
The effect of emodin on cell proliferation was
measured by 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenylte-trazolium bromide (MTT) assay. Cells were cultured in
96-well plates at a density of 1 000 cells/well with
100 μL of culture medium. After 2 days incubation, cells were
treated with different concentrations of emodin (10, 20,
30 and 40 μmol/L) and DMSO (final concentration,
0.01%) as the control and then incubated for an
additional 24, 48 or 72 h. At the time of evaluation of cell
growth, 10 μL MTT (final concentration, 5 g/L) was added
into each well. After 4-h incubation, formazan crystals
produced by living cultured cells were dissolved with
100 μL DMSO and measured using a plate microreader (Tecan
Spectra, Wetzlar, Germany) at a wavelength of 570 nm.
The percentage of cell viability was calculated as follows:
Cell viability (%) = A570 (drug) /
A570 (control) × 100
2.3 Observation of morphologic changes
LNCaP and PC-3 cells in RPMI-1640 containing 10%
FBS were seeded into 6-well culture plates and cultured
for 48 h before the treatment with different
concentrations of emodin (10, 20, 30 and 40 µmol/L) and DMSO
(final concentration, 0.01%) as the control. The cellular
morphology was observed using a phase-contrast microscopy 48 h after emodin treatments.
2.4 Flow cytometric analysis
LNCaP cells, both adherent and floating, were pelleted
and washed with PBS. The cells were fixed in 75% ethanol at 4ºC overnight. Samples were analyzed using a
flow cytometer (Becton Dickinson FACScan, Franklin
Lakes, CA, USA). Propidium iodide (PI) staining was
used to determine the percentage of cells in different
phases of the cell cycle, and sub-G1 peaks were
presented and used to calculate the apoptosis of the cells.
Fluorescent labeling monoclonal antibody was used to
determine the expression of Fas and FasL (BD Biosciences,
San Diego, CA, USA).
2.5 DNA fragmentation assay
The cells treated with different concentrations of
emodin for 48 h were harvested. DNA was prepared
using the protocol described by genomic DNA
purification kit (Shenergy Biocolor BioScicnce & Technolgy
Company, Shanghai, China), dissolved in TE buffer,
subjected to 2% agarose gel electrophoresis at 50 V for
40 min, stained with ethidium bromide, then photographed
under ultraviolet (UV) light.
2.6 Reverse transcriptase polymerase chain reaction
(RT-PCR) analysis
Total RNA was extracted from treated LNCaP cells
using TRIzol reagent (MBI Fermentas, Burlington, Ontario,
Canada) following the manufacturer's instructions, and a
portion of total RNA (2 μg) was transcribed reversibly
with the M-MuL V reverse transcriptase in the presence
of a random hexamer primer. The resulting cDNA
preparation was subjected to PCR amplification using a PCR
kit from TaKaRa Biotech, Dalian, China. The
primers and annealing temperature are shown in Table 1. The
PCR products were analyzed by electrophoresis on a
1.5% agarose gel, stained with ethidium bromide, and
then photographed under UV light. β-actin was used to
normalize the quantity of cDNA.
2.7 SDS-polyacrylamide gel electrophoresis and
Western blot analysis
LNCaP cells were treated with emodin for different
doses and times. Both adherent and floating cells were
harvested and lysed with cell lyses buffer
(50 mmol/L Tris·HCl, pH 8.0, 150 mmol/L NaCl, 0.1% SDS,
100 µg/mL of PMSF, 1 µg/mL of aprotinin, and 1% NP-40). Cell
extracts were quantified according to the BCA method.
For Western blot analysis, 40 µg of protein extract was
separated by electrophoresis on 10% SDS-PAGE, and electroblotted onto nitrocellulose membrane. After
blocking and washing, the membrane was incubated with human specific anti-AR, anti-p53 (BD Biosciences)
and anti-p21waf1/cip1 antibodies (Cell Signalling, Beverly,
MA, USA) at 4ºC for 12 h, followed by the incubation
with peroxidase-labeled second antibody for 1 h at
room temperature. Immunoreactive bands were visualized using enhanced chemiluminescence (Santa
Cruz, San Diego, CA, USA). β-tubulin (BD
Biosciences) was used to normalize the quantity of the protein on
the blot.
2.8 Statistical analysis
All the measurement data were analyzed and expressed
as the mean ± SD. Results were considered significant if
P < 0.05 was obtained using an appropriate analysis of
variance procedure and unpaired t-test.
3 Results
3.1 Emodin inhibited the proliferation of prostate
cancer cells
We first examined the effect of emodin on prostate
cancer cell proliferation. LNCaP cell growth was checked
in the presence of various concentrations of emodin
using MTT assay. MTT results showed that the cell growth
was inhibited by emodin in a dose-dependent and
time-dependent manner (Figure 1A). Observation of
morphologic changes also showed that the number of LNCaP
cells decreased and altered in morphologic characteristic
obviously after being cultured with emodin. Treatment
with different concentrations of emodin for 48 h resulted
in cell shrinkage, a rounded morphology and fuzzy cell
boundary, and eventually cells detached from the substratum. In contrast, cells incubated in the control
medium were well spread with a flattened morphology
(Figure 2). Meanwhile, we also studied the antiproliferative
effect of emodin in AR-less PC-3 cells at various concentrations. The results showed that PC-3 cells were
more resistant to the emodin-mediated antiproferative
effect than LNCaP cells (Figure 1B).
3.2 Emodin induced cell apoptosis in LNCaP cells
To determine the apoptosis of LNCaP cells induced
by emodin, flow cytometric analysis and DNA
fragmentation assay were carried out. Using flow
cytometry, apoptosis was confirmed by the appearance of a
sub-G1 peak. The apoptosis rate rose as the concentration of
emodin increased and reached a maximum at 40 µmol/L.
This suggests that emodin-induced apoptosis was
dose-dependent (Figure 3A). When LNCaP cells were
cultured with various concentrations of emodin for 48 h,
marked DNA fragmentation was observed in a dose-dependent manner (Figure 4A). However, the
sub-G1 peak and DNA fragmentation (Figures 3B and 4B) were not
found in the treated PC-3 cells.
3.3 Emodin decreased the expression of AR and
PSA, and increased the expression of p53 and p21 in LNCaP
cells
The AR plays an important role in the prostate cancer
cell proliferation, and p53 gene is an extensive tumor
suppressor that can lead to the induction of a downstream
target gene p21waf1/cip1 to inhibit the cell cycle and cause cell
growth arrest. To determine whether the inhibitions of
the cell proliferation by emodin are mediated by AR and
p53-p21 pathways, RT-PCR was performed to detect the
expression levels of AR, p53 and p21 in emodin-treated
LNCaP cells. Because the PSA is the major target of AR,
the expression of PSA was also determined. The results
showed that the expression of AR and PSA decreased
(Figure 5A) and the expression of p53 and p21 increased
(Figure 5B) significantly as the emodin concentrations were
increased. To demonstrate further the effect of emodin
on AR, p53 and p21 protein expressions, Western blot
analysis was used to evaluate their protein levels. The
results illustrated in Figure 5C demonstrated that the
expression of AR protein was decreased and that the
expression of p53 and p21 proteins was increased
significantly by emodin, consistent with the effect of emodin
on mRNA expression. Therefore, we concluded that the
proliferative inhibition of LNCaP cell induced by emodin
might be related to the AR and p53-p21 pathway.
3.4 Emodin enhanced caspase-3,and -9 expression and
increased Bax/Bcl-2 ratio in LNCaP cells
There are two typical apoptosis pathways: death
ligand/receptor (Fas)-mediated (involving caspase-8,
death-inducing signal) and chemical-induced (involving
caspase-9, mitochondrial pathway) apoptosis. To
investigate the pathways of emodin-induced LNCaP cells
apoptosis, the expression of caspase-3, -8 and -9, Bax,
Bcl-2, Fas and FasL was determined. After 48 h
treatment with emodin, the expression of Fas and FasL was
measured using flow cytometry. There were no
differences of the expression of Fas and FasL between the
control cells and emodin treated cells (Figure 6).
RT-PCR was used to determine the expression of
caspase-3, -8 and -9, Bax, Bcl-2 and Fas after 48 h emodin treatment.
The results showed that the expression of caspase-3 and
-9 increased. Caspase-8 and Fas had almost no changes
as emodin concentrations increased (Figure 7A).
Exposure of LNCaP cells to different concentrations of
emodin resulted in the increase of Bax levels and the
decrease of Bcl-2 levels after 48 h of treatment (Figure 7B).
Therefore, the above data showed that emodin induced
the apoptosis of LNCaP using a mitochondrial pathway
instead of a death-inducing signal.
4 Discussion
The herb Rheum palmatum has been used as a Chinese medicine for more than ten years. Emodin is the
major active constituent of Rheum palmatum [6, 7].
Pharmacological studies have demonstrated that emodin
has antitumor, antibacterial, diuretic and vasorelaxant
effects [8_10]. Emodin can cause a marked decrease in
cell proliferation and an increase in apoptosis in many
types of cancer cells, including lung cancer, breast
cancer and uterine cervix cancer [22, 23]. Although it has
been claimed to have potent anticancer activity in
prostate cancer cells [11], the molecular mechanisms of
emodin that produce its biological effects in prostate cancer
cells has not been well-characterized. The present study
investigated the effects and mechanisms of emodin in
human prostate cancer cell lines LNCaP.
AR is highly involved in the proliferation of prostate
cancer cells [24]. Many plant chemicals, such as resveratrol [25], quercetin [26] and gum mastic [27]
were reported as potential chemopreventive agents for
prostate cancer because of their effects on inhibition of
AR expression. Biancolella et al. [28, 29] reported that
by analysis of microarray some agents can influence the
growth of the prostate cancer cells by modulating the
expression of several androgen metabolic genes, the AR
co-regulators (AR; CCND1), signal transduction related
genes (e.g. ERBB2; V-CAM;
SOS1) and androgen-regulated genes (e.g. PSA). PSA is a major target gene of
AR, which induces PSA expression through three androgen-responsive elements located in the proximal 6 kb
promoter of the PSA gene [30, 31]. When AR expression decreased, PSA expression also decreased. As a
result of AR downregulation by emodin, PSA expression
also decreased in our experiment. Therefore, it is likely
that the inhibition of expression and function of the AR
by emodin could reduce LNCaP cell proliferation.
The p53 gene is a tumor suppressor gene. As a
transcription factor, p53 protein regulates the expression of
several growth control genes involved in cell cycle
progression, DNA repair, apoptosis and angiogenesis
[14_16]. The activation of p53 can cause induction of p21,
which, as the cyclin-dependent kinase inhibitor, in turn
inhibits DNA replication [32] and cyclin dependent
kinase (CDK)-cyclin activity and arrests the cell cycle at the
G1 or G2 checkpoint [33, 34]. In our study, the increase in
p53 and p21 expression might contribute to the inhibition
of the cell proliferation induced by emodin.
Apoptosis is a major form of cell death and essential
for normal development and for the maintenance of homeostasis. In addition, current antineoplastic therapies,
chemotherapy and radiation therapy are likely to be
affected by the apoptotic tendencies of cells; thus this
process obvious has therapeutic implications [35]. During
apoptosis, certain characteristic morphologic events, such
as nuclear condensation, nuclear fragmentation and cell
shrinkage, and biochemical events, such as DNA fragmentation, occur [36]. In the present study, the
morphological changes were observed, including cell
shrinkage in emodin-treated LNCaP cells,
sub-G1 peak formation in flow cytometry analysis and cell death (MTT assay).
The Bcl-2 family proteins constitute important
control mechanisms in the regulation of apoptosis. Some
members of this family, such as Bcl-2 and
Bcl-XL, suppress apoptosis, whereas others, such as Bax and Bid,
promote apoptosis. The balance between these two groups determines the fate of cells in many apoptosis
systems [37]. In the present study, emodin-induced
apoptosis of LNCaP cells appeared to be associated with
the increased expression of Bax and decreased
expression of Bcl-2. Indeed, this result is consistent with
previous observations in which Bax overexpression and
Bcl-2 decrease induced cell apoptosis due to a variety of stimuli,
including chemotherapeutic agents such as paclitaxel and
oridonin [38, 39].
Caspases, a family of cysteine proteases, play a
critical role in the apoptosis and are responsible for many
of the biochemical and morphological changes
associated with apoptosis [40]. There are two prototypical
pathways for induction of apoptosis in mammalian cells
induced by Bax (involving caspase-9) and Fas (involving
caspase-8). To investigate the pathway of
emodin-induced LNCaP cells death, the expression levels of
caspase-3, -8 and -9, Fas and FasL were determined in
our experiment. RT-PCR results suggest that the
expression of caspase-3 and -9 increased, but caspase-8
and Fas almost had no changes in LNCaP cells with emodin treatments. Emodin induced LNCaP cell death
through a mitochondrial pathway instead of through a
death-inducing signal.
In summary, the present study demonstrated that
emodin inhibited the proliferation and induced apoptosis
of LNCaP cells. The growth inhibition of LNCaP cells
induced by emodin was mediated by a decrease in the
expression and function of the AR and an increase in the
expression of p53 and p21. Emodin induced apoptosis
via the mitochondrial pathway, as evidenced by the
increased expression of caspase-3, -9 and
increased Bax/Bcl-2 ratio. It is proposed that emodin may be a useful
chemopreventive/chemotherapeutic agent for prostate
cancer.
Acknowledgment
This study was supported by the Natural Science
Foundation of Shandong Province (No. Y2005C29) and
the National Natural Science Foundation of China (No.
30470820 and No. 30670581).
References
1 Greenlee RT, Murray T, Bolden S, Wingo PA. The prostate:
an increasing medical problem. Prostate 1990; 16: 39_48.
2 Hanks GE. Long-term control of prostate cancer with radiation.
Past, present, and future. Urol Clin N Am 1996; 23:
605_16.
3 Garnick MB. Hormonal therapy in the management of prostate
cancer: from Higgins to the present. Urology 1997; 49: 5_15.
4 Surh YJ. Cancer chemoprevention with dietary phytochemicals.
Nat Rev Cancer 2003; 3: 768_80.
5 Zhang HN, Yu CX, Zhang PJ, Chen WW, Jiang AL, Kong F,
et al. Curcumin downregulates homeobox gene NKX3.1 in prostate
cancer cell LNCaP. Acta Pharmacol Sin 2007; 28:
423_30.
6 Tsai TH, Chen CF. Ultraviolet spectrum identification of
emodin in rabbit plasma by HPLC and its pharmacokinetics
application. Asia Pac J Pharmacol 1992; 7: 53_6.
7 Liang JW, Hsiu SL, Huang HC, Lee-Chao PD. HPLC analysis
of emodin in serum, herbs and Chinese herbal prescriptions. J
Food Drug Anal 1993; 1: 251_7.
8 Koyama M, Kelly TR, Watanabe KA. Novel type of
potential anticancer agents derived from chrysophanol and emodin.
Some structure-activity relationship studies. J Med Chem
1988; 31: 283_4.
9 Zhou XM, Chen QH. Biochemical study of Chinese rhubarb.
XXII. Inhibitory effect of anthraquinone derivatives on
Na+-K+-ATPase of the rabbit renal medulla and their diuretic action.
Yao Xue Xue Bao 1988; 23: 17_20.
10 Huang HC, Chu SH, Chao PD. Vasorelaxants from Chinese
herbs, emodin and scoparone, possess immunosuppressive
properties. Eur J Pharmacol 1991; 198: 211_3.
11 Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The
release of cytochrome c from mitochondria: a primary site for
Bcl-2 regulation of apoptosis. Science 1997; 275:
1132_6.
12 Hovenian MS, Deming CL. The heterologous growth of cancer
of the human prostate. Surg Gynecol Obstet
1948; 86: 29_35.
13 Ross RK, Bernstein L, Judd H, Hanisch R, Pike M, Henderson
B. Serum testosterone levels in young black and white men. J
Natl Cancer Inst 1986; 76: 45_8.
14 Vogelstein B, Lane D, Levine, AJ. Surfing the p53 network.
Nature 2000; 408: 307_10.
15 Prives C, Hall PA. The p53 pathway. J
Pathology 1999; 187: 112_26.
16 Vousden KH. p53: death star. Cell 2000; 103:
691_4.
17 Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alenmri
ES. Autoactivation of procaspase-9 by Apaf-1-mediated
oligomerization. Mol Cell 1998; 1: 949_57.
18 Sun XM, Macfarlane M, Zhuang J, Wolf BB, Green DR,
Cohen GM. Distinct caspase cascades are initiated in
receptor-mediated and chemical-induced apoptosis. J Biol Chem
1999; 274: 5053_60.
19 Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell
survival. Science 1998; 281: 1322_6.
20 Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J,
et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c
from mitochondria blocked. Science 1997; 275: 1129_32.
21 Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D,
Reed JC. Bax directly induces release of cytochrome c from
isolated mitochondria. Proc Natl Acad Sci USA 1998; 95:
4997_5002.
22 Huang Q, Shen HM, Shui GH, Wenk MR, Ong CN. Emodin
inhibits tumor cell adhesion through disruption of the
membrane lipid raft-associated integrin signaling pathway. Cancer
Res 2006; 66: 5807_15.
23 Fu ZY, Han JX, Huang HY. Effects of emodin on gene
expression profile in small cell lung cancer NCI-H446 cells. Chin
Med J 2007; 120: 1710_5.
24 Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ.
Disruption of androgen receptor function inhibits proliferation of
androgen-refractory prostate cancer cells. Cancer
Res 2002; 62: 1008_13.
25 Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the
expression and function of the androgen receptor in LNCaP
prostate cancer cells. Cancer Res 1999; 59: 5892_5.
26 Xing N, Chen Y, Mitchell SH, Young CY. Quercetin inhibits
the expression and function of the androgen receptor in LNCaP
prostate cancer cells. Carcinogenesis 2001; 22: 409_14.
27 He ML, Yuan HQ, Jiang AL, Gong AY, Chen WW, Zhang PJ,
et al. Gum mastic inhibits the expression and function of the
androgen receptor in prostate cancer cells. Cancer 2006; 106:
2547_55.
28 Biancolella M, Valentini A, Minella D, Vecchione L, D'Amico F,
Chillemi G, et al. Effects of dutasteride on the expression of genes
related to androgen metabolism and related pathway in human
prostate cancer cell lines. Invest New Drugs 2007; 25: 491_7.
29 Valentini A, Biancolella M, Amati F, Gravina P, Miano R,
Chillemi G, et al. Valproic acid induces neuroendocrine
differentiation and UGT2B7 up-regulation in human prostate
carcinoma cell line. Drug Metab Dispos 2007; 35: 968_72.
30 Cleutjens K, Vander KH, Van EC, Van RH, Faber PW, Trapman
J. An androgen response element in a far upstream enhancer
region is essential for high, androgen-regulated activity of the
prostate-specific antigen promoter. Mol Endocrinol 1997;
11: 148_61.
31 Cleutjens K, Van EC, Vander KH, Brinkman AO, Trapman J.
Two androgen response regions cooperate in steroid hormone
regulated activity of the prostate specific antigen promoter. J
Biol Chem 1996; 271: 6379_88.
32 Chen X, Barqonetti J, Prives C. p53, through p21
(WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 1995; 55:
4257_63.
33 Colman MS, Afshari CA, Barrett JC. Regulation of p53
stability and activity in response to genotoxic stress. Mutat Res
2000; 462: 179_88.
34 Winters ZE. P53 pathways involving G2 checkpoint
regulators and the role of their subcellular
localization. J R Coll Surg Edinb 2002; 47: 591_8.
35 Green DR, Bissonnette RP, Cotter TG. Apoptosis and cancer.
Important Adv Oncol 1994; 11: 37_52.
36 Hsu SL, Yin SC, Liu MC, Reichert U, Ho WL. Involvement of
cyclin-dependent kinase activities in CD437-induced
apoptosis. Exp Cell Res 1999; 252: 332_41.
37 Kroemer G. The proto-oncogene Bcl-2 and its role in
regulating apoptosis. Nat Med 1997; 3: 614_20.
38 Strobel T, Swanson L, Korsmeyer S, Cannistra SA. Bax
enhances paclitaxel-induced apoptosis through a
p53-independent pathway. Proc Natl Acad Sci USA 1996; 93:
14094_9.
39 Huang J, Wu LJ, Tashiro S, Onodera S, Ikejima T. Bcl-2
up-regulation and P-p53 down-regulation account for the low
sensitivity of murine L929 fibrosarcoma cells to
oridonin-induced apoptosis. Biol Pharm Bull 2005; 28: 2068_74.
40 Cohen GM. Caspases: the executioners of apoptosis. Biochem
J 1997; 326: 1_16.
|